vigabatrin
E874312
Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
GABAergic drug
ⓘ
anticonvulsant ⓘ antiepileptic drug ⓘ pharmaceutical drug ⓘ |
| actsOn | GABA transaminase NERFINISHED ⓘ |
| administeredAs | oral powder for solution ⓘ |
| affects | visual pathways ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIndication |
infantile spasms in children 1 month to 2 years of age
ⓘ
refractory complex partial seizures in adults ⓘ |
| belongsToClass | succinimide analogs ⓘ |
| chemicalName | (±)-4-amino-5-hexenoic acid ⓘ |
| contraindicatedIn |
hypersensitivity to vigabatrin
ⓘ
patients with pre-existing significant visual field defects ⓘ |
| developedFor | epilepsy treatment ⓘ |
| eliminationRoute | renal excretion ⓘ |
| hasAdverseEffect |
behavioral changes
ⓘ
dizziness ⓘ fatigue ⓘ retinal toxicity ⓘ somnolence ⓘ weight gain ⓘ |
| hasATCCode | N03AG04 ⓘ |
| hasBlackBoxWarning | risk of permanent vision loss ⓘ |
| hasChemicalFormula | C6H11NO2 ⓘ |
| hasEffectOn | increases inhibitory neurotransmission ⓘ |
| hasHalfLife | approximately 5 to 8 hours in adults ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMechanismOfAction | irreversible GABA transaminase inhibitor ⓘ |
| hasPregnancyCategory | may cause fetal harm (risk–benefit assessment required) ⓘ |
| hasRiskManagementProgram | REMS program in the United States NERFINISHED ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
oral solution ⓘ oral tablet ⓘ |
| hasSeriousAdverseEffect |
peripheral visual field constriction
ⓘ
permanent visual field loss ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| increasesLevelOf | gamma-aminobutyric acid in the brain ⓘ |
| isAnalogOf | gamma-aminobutyric acid ⓘ |
| mayCause | MRI signal changes in infants ⓘ |
| notSignificantlyMetabolizedBy | cytochrome P450 enzymes ⓘ |
| requiresMonitoring | periodic visual field testing ⓘ |
| riskIncreasesWith |
higher cumulative dose
ⓘ
longer duration of therapy ⓘ |
| shouldBeUsedWhen | benefits outweigh risk of vision loss ⓘ |
| usedFor |
West syndrome
NERFINISHED
ⓘ
infantile spasms ⓘ refractory partial seizures ⓘ treatment-resistant epilepsy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.